Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SHIFT-IBD: Switching to High-efficacy Anti-IL-23 Guselkumab in Ustekinumab-exposed Persons With Active IBD

NCT07245394 is registered in ClinicalTrials.gov with TIDHI Innovation Inc. as lead sponsor.

NCT NCT07245394
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07245394 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SHIFT-IBD: Switching to High-efficacy Anti-IL-23 Guselkumab in Ustekinumab-exposed Persons With Active IBD
Lead sponsor
TIDHI Innovation Inc.
Phase
Observational
Overall status
Recruiting
Start date
January 29, 2026
Completion date
November 1, 2028
Enrollment
200 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease (cd), ibd-unclassified (ibd-u), inflammatory bowel disease (ibd), ulcerative colitis (uc)